Currently, the focus on DR5 antagonists has intensified, showing significant promise for treating conditions associated with DR5 hyperactivation, such as severe viral infections (Peng H. et al., 2022), inflammation, ischemia-reperfusion injury (Xiaochun et al., 2022; Zhang, 2018; Liu, 2018), and autoimmune diseases. The gene discussed is TNFRSF10B; the disease is autoimmune disease.